Lexeo Therapeutics Inc Stock Price, News & Analysis

Lexeo Therapeutics (Nasdaq: LXEO) closed an underwritten public offering and a concurrent private placement on Oct 20, 2025, raising approximately $153.8 million in gross proceeds before fees and expenses.

Details: the public offering sold 17,968,750 common shares at $8.00 per share (including full exercise of a 2,343,750-share underwriter option) for gross proceeds of about $143.8 million. The concurrent private placement sold pre-funded warrants to purchase 1,250,015 shares to Balyasny Asset Management for about $10 million. Joint book-runners and placement agents were named and registration materials were filed with the SEC.

Lexeo Therapeutics (Nasdaq: LXEO) priced an underwritten public offering and a concurrent private placement to raise approximately $135 million in gross proceeds before underwriting discounts, commissions and expenses. Lexeo offered 15,625,000 common shares at $8.00 per share and granted a 30‑day option to underwriters to purchase up to 2,343,750 additional shares. Concurrently, Lexeo agreed to sell 1,250,015 pre‑funded warrants to Balyasny Asset Management at $7.9999 per warrant. The transactions are expected to close on or about October 20, 2025, subject to customary closing conditions.

Lexeo Therapeutics (Nasdaq: LXEO) announced on October 16, 2025 that it commenced an underwritten public offering and a concurrent private placement of common stock and, for certain investors, pre-funded warrants to purchase common stock.

The company said it will grant underwriters a 30-day option to buy additional shares, named joint book-runners and stated the offering is being made under a Form S-3 registration statement declared effective by the SEC. The offering and private placement are subject to market and customary conditions and may not be completed.

Lexeo Therapeutics (Nasdaq: LXEO) reported FDA openness to pooling ongoing Phase I/II data with pivotal study data to support an Accelerated Approval BLA for LX2006 in Friedreich ataxia cardiomyopathy and said the FDA may allow the LVMI co-primary endpoint to be assessed earlier than 12 months. Interim clinical data (n=16 with >6 months follow-up) showed mean LVMI reductions of 18% at 6 months and 23% at 12 months (6 participants with abnormal baseline LVMI), dose-dependent improvements in mid/high cohorts, a 2.0-point mean mFARS improvement, and broad reductions in high-sensitivity troponin I. Safety was generally acceptable with no Grade 3+ SAEs and one previously disclosed Grade 2 myocarditis. Lexeo plans to start the pivotal study in H1 2026 pending final protocol and comparability work.

Lexeo Therapeutics (NASDAQ:LXEO) reported significant Q2 2025 developments and financial results. The company received FDA Breakthrough Therapy designation for LX2006 for Friedreich ataxia treatment, demonstrating meaningful cardiac and neurologic improvements. Eight participants were dosed in the Phase I/II HEROIC-PKP2 trial of LX2020 for PKP2-ACM.

The company secured an $80 million equity financing and ended Q2 with $152.5 million in cash and equivalents, extending runway into 2028. Lexeo also formed a strategic partnership with Perceptive Xontogeny Venture Funds and venBio Partners for RNA-based cardiac therapies, and appointed Louis Tamayo as CFO. Q2 net loss was $26.1 million ($0.60 per share) compared to $21.2 million ($0.64 per share) in Q2 2024.

Lexeo Therapeutics (Nasdaq: LXEO) has achieved a significant milestone as its drug candidate LX2006 received FDA Breakthrough Therapy designation for treating Friedreich ataxia (FA). The designation was based on promising interim clinical data from Phase I/II trials showing meaningful improvements in cardiac biomarkers and functional measures.

The drug has demonstrated clinically significant improvements in cardiac and neurologic functional measures, with increased frataxin expression observed in all cardiac biopsy participants at three months post-treatment. To date, 17 participants have been treated across two trials. The company plans to initiate a registrational study by early 2026.

Additionally, LX2006 has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, aimed at facilitating faster patient access to promising therapies.

Lexeo Therapeutics (NASDAQ:LXEO) has announced a strategic partnership to develop novel RNA-based therapeutics for genetic cardiac diseases through a new entity backed by up to $40 million in private equity financing from Perceptive Xontogeny Venture Funds and venBio Partners.

The new venture will combine Lexeo's expertise in cardiac genetic medicines with a novel non-viral RNA delivery platform. Lexeo will receive a double-digit percentage equity stake, milestone payments, royalties, and opt-in rights to certain programs. The genetic and precision cardiology market is projected to grow from $13 billion in 2025 to nearly $40 billion by 2033.

Lexeo Therapeutics (LXEO) has secured an $80 million equity financing through a private placement of common stock and warrants. The company will issue 20,790,120 shares of common stock and pre-funded warrants to purchase 6,963,556 shares, with each share accompanied by a warrant to purchase one-half share. The purchase price is set at $2.8825 per share. The financing was co-led by Frazier Life Sciences and Janus Henderson Investors, with participation from several other institutional investors. The proceeds, combined with existing cash reserves, will extend Lexeo's cash runway into 2028 and fund the development of their cardiovascular genetic medicine pipeline, including the potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy.

Lexeo Therapeutics (NASDAQ: LXEO) reported Q1 2025 financial results and operational updates. The company announced positive interim data for LX2006 in Friederich ataxia cardiomyopathy, with frataxin expression and LVMI improvements exceeding target thresholds. The high-dose cohort showed a 115% increase in cardiac frataxin expression and a 25% mean reduction in LVMI. Lexeo plans to initiate a registrational study by early 2026. For LX2020 in PKP2-ACM, interim data showed promising results with 71-115% increases in PKP2 protein expression. The company reported cash position of $106.9 million, redeployed $20 million to clinical programs, and implemented a 15% workforce reduction. Q1 2025 net loss was $32.7 million ($0.99/share) compared to $21.7 million ($0.77/share) in Q1 2024.